Changing Trends in Computational Drug Repositioning
Efforts to maximize the indications potential and revenue from drugs that are already marketed are largely motivated by what Sir James Black, a Nobel Prize-winning pharmacologist advocated—“The most fruitful basis for the discovery of a new drug is to start with an old drug&r...
Main Authors: | Jaswanth K. Yella, Suryanarayana Yaddanapudi, Yunguan Wang, Anil G. Jegga |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/11/2/57 |
Similar Items
-
Computational Drug Repositioning: Current Progress and Challenges
by: Younhee Ko
Published: (2020-07-01) -
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
by: Sha Zhu, et al.
Published: (2022-01-01) -
Drug Repositioning for Hand, Foot, and Mouth Disease
by: Ran Yan, et al.
Published: (2022-12-01) -
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
by: Daniele Parisi, et al.
Published: (2020-01-01) -
Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov
by: Eric Wen Su, et al.
Published: (2017-03-01)